This program examines the evolving role of TROP2 antibodydrug conjugates ADCs in nonsmallcell lung cancer including emerging ESMO 2026 data platform differences biomarker considerations and evidencebased treatment sequencing Through casebased guidance learners will explore patient selection and proactive management of TROP2 ADCassociated toxicities including neutropenia diarrhea stomatitis ocular events and interstitial lung diseasepneumonitis
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
97% of listed courses are free
292 of a sample of 300 are free · 545 courses listed here.
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Clinical Informatics
- Clinician Wellness & Burnout
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Geriatric Psychiatry
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Infectious Disease
- Laryngology
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Neonatal-Perinatal Medicine
- Nephrology
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Obstetrics & Gynecology
- Otology & Neurotology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Hematology-Oncology
- Pediatric Infectious Diseases
- Pediatric Otolaryngology
- Psychopharmacology
- Psychotic Disorders
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Live
- Credit · Up to 1.5 credits
- Commercial Support
-
WhenOct 24, 2026
-
Clinical Care Options, LLC (dba Decera Clinical Education) HER2- and TROP2-Directed ADCs in NSCLC: Patient Selection, Treatment Sequencing, and Toxicity Management in a Rapidly Evolving Landscape
-
Clinical Care Options, LLC (dba Decera Clinical Education) TROP2 ADC Decision Lab in NSCLC: What to Use Now, What to Watch Next, and How to Keep Patients Safe
-
Clinical Care Options, LLC (dba Decera Clinical Education) TROP2-Directed ADCs in mTNBC: Personalizing Treatment Sequencing and Supportive Care
-
Answers in CME Inc. (AiCME) What s Now and What s Next for ADCs in NSCLC? Integrating HER2- and TROP2-Targeted Therapies Into the Evolving Treatment Landscape
-
Efficient CME, CME Outfitters, LLC Addressing Unmet Needs in Non-Small Cell Lung Cancer: The Evolving Role of TROP2-Directed Therapies
-
National Association for Continuing Education Integrating TROP2-Directed ADCs into TNBC Treatment Plans: Novel Aspects of Efficacy and Safety Profiles
